Drugs / Psilocybin
Psilocybin
Trials 247 · started per year
today
1
1
1
2
1
2
4
3
4
4
6
5
20
19
33
41
42
53
4
1
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 019 trials · 1 met primary | ||||||
| Phase 0 | NCT06102434 | Feb → May 2029 | substance-related disorder | University of California, Los Angeles | Suspended | No outcome recorded |
| Phase 0 | NCT07565493 | Aug 2026 → Jun 2028 expected | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 0 | NCT06760533 | Aug → Dec 2026 expected | irritable bowel syndrome | NYU Langone Health | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07118332 | Jul 2026 → Oct 2027 expected | — | Yale University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06724289 | Mar 2026 → Aug 2027 expected | — | University of Virginia | Recruiting | No outcome recorded |
| Phase 0 | NCT06798636 | Oct 2025 → Aug 2026 overdue | — | Imperial College London | Recruiting | No outcome recorded |
| Phase 0 | NCT06464367 | May 2025 → Dec 2027 expected | migraine disorder | Yale University | Recruiting | No outcome recorded |
| Phase 0 | NCT06656702 | Apr 2025 → Jan 2027 expected | amyotrophic lateral sclerosis | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 0 | NCT06899594 | Apr 2025 → Mar 2027 expected | methamphetamine dependence | Kevin Murnane | Recruiting | No outcome recorded |
| Phase 0 | NCT05068791 | Nov 2023 → Dec 2026 expected | fibromyalgia | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 0 | NCT05958758 | Sep 2023 → Apr 2025 | — | The Roots to Thrive Society for Psychedelic Therapy | Unknown | No outcome recorded |
| Phase 0 | NCT05227742 | Aug 2023 → Mar 2026 | — | University of Alabama at Birmingham | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT05252598 | Jan → Aug 2023 | anxiety, mood disorder, poisoning, sleep disorder | Optimi Health Corporation | Withdrawn | No outcome recorded |
| Phase 0 | NCT05546658 | Nov 2022 → Dec 2026 expected | obsessive-compulsive disorder | Johns Hopkins University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04522804 | Oct 2021 → Jun 2022 | cancer | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT04501653 | Jun 2021 → Mar 2023 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT04123314 | Mar 2021 → Jun 2027 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia, depressive disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 0 | NCT03604744 | Mar 2019 → Apr 2021 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 0 | NCT00957359 | Feb 2009 → Sep 2018 | cancer | NYU Langone Health | Completed | Met primary |
| Phase 172 trials · 1 met primary · 1 missed | ||||||
| Phase 1 | NCT07833761 | Dec 2026 → Dec 2029 expected | borderline personality disorder, depressive disorder | University of Minnesota | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06988319 | Nov 2026 → Dec 2027 expected | chronic pain syndrome | Oregon Health and Science University | Recruiting | No outcome recorded |
| Phase 1 | NCT07818564 | Nov 2026 → Nov 2027 expected | — | Brown University | Recruiting | No outcome recorded |
| Phase 1 | NCT07360301 | Oct 2026 → Feb 2028 expected | — | University of Wisconsin, Madison | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07607938 | Sep 2026 → Aug 2030 expected | atypical depressive disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 1 | NCT07406828 | Jul 2026 → Aug 2027 expected | — | Trent Emerick | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07386730 | Jun 2026 → Feb 2030 expected | — | Jennifer Mitchell | Recruiting | No outcome recorded |
| Phase 1 | NCT07347405 | May 2026 → Jan 2028 expected | obsessive-compulsive disorder | Francisco A Moreno | Recruiting | No outcome recorded |
| Phase 1 | NCT07506395 | May 2026 → May 2027 expected | post-traumatic stress disorder | University of New Mexico | Recruiting | No outcome recorded |
| Phase 1 | NCT07516405 | Apr 2026 → Mar 2028 expected | — | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT06818994 | Apr 2026 → Jun 2027 expected | — | Gustavo Vazquez | Recruiting | No outcome recorded |
| Phase 1 | NCT07053917 | Feb 2026 → Feb 2027 expected | hemiplegia, intracerebral hemorrhage, ischemic stroke | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT07275970 | Feb → Mar 2026 overdue | post-traumatic stress disorder | Suzanne "Sue" Sisley MD | Recruiting | No outcome recorded |
| Phase 1 | NCT07079930 | Dec 2025 → Nov 2026 expected | — | Hadassah Medical Organization | Recruiting | No outcome recorded |
| Phase 1 | NCT07490353 | Nov 2025 → May 2028 expected | atypical depressive disorder, major depressive disorder | Medical University of Vienna | Recruiting | No outcome recorded |
| Phase 1 | NCT06367738 | Nov 2025 → Dec 2026 expected | — | University of California, Berkeley | Recruiting | No outcome recorded |
| Phase 1 | NCT06692192 | Aug 2025 → Dec 2027 expected | — | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 1 | NCT06919640 | Jun 2025 → Apr 2028 expected | chronic pain syndrome | Joshua Woolley, MD, PhD | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06160284 | May 2025 → Jan 2027 expected | substance-related disorder | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT06615908 | May 2025 → Jun 2027 expected | — | University of Calgary | Recruiting | No outcome recorded |
| Phase 1 | NCT06796361 | Apr 2025 → Aug 2026 overdue | — | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 1 | NCT06835699 | Apr 2025 → Aug 2026 overdue | — | Johns Hopkins University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06884514 | Apr 2025 → May 2026 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT06899334 | Apr 2025 → Aug 2026 overdue | — | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 1 | NCT05866471 | Jan 2025 → Nov 2027 expected | congenital vagal hyperreflexivity | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 1 | NCT05562973 | Jan → Dec 2025 | post-traumatic stress disorder | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 1 | NCT06450210 | Dec 2024 → Jul 2026 overdue | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT06430541 | Nov 2024 → Dec 2026 expected | breast cancer, ovarian cancer | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT06644170 | Nov 2024 → Sep 2025 | hematopoietic and lymphoid system neoplasm, metastatic malignant neoplasm | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT06660381 | Nov 2024 → Nov 2026 expected | cannabis dependence | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT06731621 | Nov 2024 → Aug 2027 expected | autism spectrum disorder | Centre for Addiction and Mental Health | Recruiting | No outcome recorded |
| Phase 1 | NCT06442423 | Oct 2024 → Dec 2027 expected | anxiety, major depressive disorder, obsessive-compulsive disorder, post-traumatic stress disorder +1 | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT06506019 | Oct 2024 → Sep 2026 overdue | bipolar depression | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 1 | NCT06299319 | Sep 2024 → Sep 2026 | obsessive-compulsive disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 1 | NCT06407635 | Jun 2024 → Mar 2026 overdue | post-traumatic stress disorder | Johns Hopkins University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06355414 | Apr 2024 → Dec 2026 expected | chronic pain syndrome, depressive disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT05265546 | Mar 2024 → Dec 2028 expected | perceptual disorders | University of California, Berkeley | Recruiting | No outcome recorded |
| Phase 1 | NCT05592379 | Nov 2023 → Feb 2025 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT05042466 | Sep 2023 → Aug 2025 | nervous system injury | NWTraumatherapies | Unknown | No outcome recorded |
| Phase 1 | NCT05698511 | Jul 2023 → Jan 2026 overdue | — | Robin Carhart-Harris, PhD, MA | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05370911 | Jul 2023 → Feb 2026 overdue | obsessive-compulsive disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05227612 | Jun 2023 → Sep 2025 | major depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT05467761 | Jun 2023 → Mar 2024 | — | University of Wisconsin, Madison | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT05220046 | Apr 2023 → May 2026 overdue | biliary tract cancer, malignant pancreatic neoplasm | University of Nebraska | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05322954 | Mar 2023 → Mar 2024 | methamphetamine dependence | University of Wisconsin, Madison | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05557643 | Jan 2023 → Sep 2024 | depressive disorder | University of Utah | Completed | Met primary |
| Phase 1 | NCT05506982 | Nov 2022 → Apr 2024 | cancer, hematopoietic and lymphoid cell neoplasm | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT06258031 | Oct 2022 → Jun 2024 | obsessive-compulsive disorder | Imperial College London | Completed | No outcome recorded |
| Phase 1 | NCT05224336 | Oct 2022 → Mar 2024 overdue | — | University of California, San Diego | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05305105 | Jul 2022 → Oct 2024 | Lyme disease, post-treatment Lyme disease syndrome | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT05478278 | Jun 2022 → Aug 2023 | — | Usona Institute | Completed | No outcome recorded |
| Phase 1 | NCT07710027 | Oct 2021 → Mar 2022 | — | Diamond Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04424225 | Aug 2021 → Sep 2023 | perceptual disorders | University of Minnesota | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04905121 | Aug 2021 → Apr 2022 | trigeminal autonomic cephalalgia | Beckley Psytech Limited | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04218539 | Aug 2021 → Nov 2023 | migraine disorder | Yale University | Completed | Missed primary |
| Phase 1 | NCT04842045 | May 2021 → Nov 2022 | amnestic disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT04161066 | Jan 2021 → Dec 2026 expected | substance-related disorder | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 1 | NCT04052568 | Aug 2019 → Jan 2022 | anorexia nervosa | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT03806985 | Mar 2019 → Jun 2023 | traumatic encephalopathy | Yale University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03300947 | Jan 2019 → Oct 2023 | obsessive-compulsive disorder | University of Arizona | Completed | No outcome recorded |
| Phase 1 | NCT03356483 | Nov 2018 → Jul 2024 | obsessive-compulsive disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03554174 | Feb 2018 → Jul 2021 overdue | major depressive disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02950467 | Jan 2018 → Dec 2019 | depressive disorder | Joshua Woolley | Completed | No outcome recorded |
| Phase 1 | NCT03341689 | Nov 2017 → Apr 2021 | migraine disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03289949 | Mar 2017 → Jun 2030 expected | — | Gitte Moos Knudsen | Recruiting | No outcome recorded |
| Phase 1 | NCT02421263 | Apr 2015 → Jun 2020 | — | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT02243813 | Mar 2015 → May 2024 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT02163707 | Jun 2014 → Dec 2015 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT02145091 | May 2014 → Dec 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT02033707 | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01988311 | May 2013 → Jan 2014 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT00802282 | Aug 2009 → Feb 2014 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/217 trials | ||||||
| Phase 1/2 | NCT07610135 | Oct 2026 → Jun 2028 expected | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07079852 | Sep 2026 → Aug 2028 expected | — | Manoj Doss | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07499583 | Aug 2026 → Jan 2031 expected | substance-related disorder | Indiana University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07251491 | May 2026 → Mar 2028 expected | major depressive disorder, spinal cord injury | James J. Peters Veterans Affairs Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07281352 | Jan 2026 → Nov 2027 expected | major depressive disorder | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06814522 | Jan 2025 → Jun 2028 expected | — | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06471959 | Jan → Jul 2025 | — | Empower Research Inc | Unknown | No outcome recorded |
| Phase 1/2 | NCT06898606 | Sep 2024 → Aug 2026 overdue | depressive disorder | Federal University of Latin American Integration | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04754061 | Jan 2024 → Oct 2026 expected | mixed anxiety and depressive disorder | Ottawa Hospital Research Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05351541 | Dec 2023 → Jul 2026 overdue | chronic pain syndrome | Joshua Woolley, MD, PhD | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05847686 | Jun 2023 → Apr 2024 | hematopoietic and lymphoid system neoplasm, metastatic malignant neoplasm | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT04982796 | Jul 2022 → Dec 2026 expected | substance-related disorder | Portland VA Research Foundation, Inc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05301608 | Mar 2022 → Jul 2026 overdue | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04505189 | May 2021 → Dec 2023 | anorexia nervosa | Imperial College London | Completed | No outcome recorded |
| Phase 1/2 | NCT04280055 | Jan → Nov 2020 | cluster headache syndrome | Gitte Moos Knudsen | Terminated | No outcome recorded |
| Phase 1/2 | NCT02971605 | Jul 2017 → Aug 2018 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT00302744 | Apr 2004 → Dec 2008 | anxiety | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 2115 trials · 6 met primary · 2 missed | ||||||
| Phase 2 | NCT06005662 | Apr 2027 → Jul 2028 | substance-related disorder | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 2 | NCT07774702 | Feb 2027 → Feb 2032 expected | methamphetamine dependence | Peter Hendricks | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07852832 | Jan → Dec 2027 expected | nicotine dependence | University of British Columbia | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07566104 | Jan 2027 → Dec 2028 expected | major depressive disorder | University of California, Los Angeles | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07296094 | Nov 2026 → Dec 2029 expected | alcohol-related disorders | Brigham and Women's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07227909 | Nov 2026 → Jan 2029 expected | peripheral neuropathy | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07791901 | Oct 2026 → Dec 2027 expected | — | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07721467 | Oct 2026 → Dec 2030 expected | Alzheimer disease | National Institute on Aging (NIA) | Recruiting | No outcome recorded |
| Phase 2 | NCT07820033 | Sep 2026 → Dec 2028 expected | bone sarcoma, lymphoma, malignant endocrine neoplasm, melanoma | University Health Network, Toronto | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06349083 | Sep 2026 → May 2030 expected | alcohol-related disorders | NYU Langone Health | Recruiting | No outcome recorded |
| Show all 115 trials opens the full record — a long page | ||||||
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07570654 | Sep 2026 → Nov 2028 expected | post-traumatic stress disorder | COMPASS Pathways | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05398484 | May 2023 → Jan 2027 expected | cancer of unknown primary site | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 310 trials · 2 met primary | ||||||
| Phase 3 | NCT07226232 | Jul 2026 → Dec 2030 expected | major depressive disorder | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07638553 | Jun 2026 → Jun 2030 expected | alcohol-related disorders, depressive disorder | Nîmes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07703722 | Apr 2026 → Oct 2027 expected | major depressive disorder, post-traumatic stress disorder | Khyber Medical University Peshawar | Recruiting | No outcome recorded |
| Phase 3 | NCT07063862 | Jan 2026 → Aug 2027 expected | — | Bruyère Health Research Institute. | Recruiting | No outcome recorded |
| Phase 3 | NCT06247839 | Sep 2024 → Jun 2028 expected | major depressive disorder | Sharmin Ghaznavi | Recruiting | No outcome recorded |
| Phase 3 | NCT06303739 | Apr 2024 → Apr 2026 overdue | major depressive disorder | University of North Carolina, Chapel Hill | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06308653 | Mar 2024 → Jan 2026 overdue | major depressive disorder | Usona Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05711940 | Feb 2023 → Feb 2026 overdue | — | COMPASS Pathways | Active not recruiting | Met primary |
| Phase 3 | NCT05624268 | Jan 2023 → May 2025 overdue | — | COMPASS Pathways | Active not recruiting | Met primary |
| Phase 3 | NCT05163496 | Mar 2022 → Dec 2023 | COVID-19, depressive disorder, post-traumatic stress disorder | University of Washington | Completed | No outcome recorded |
| Phase not applicable12 trials · 1 met primary | ||||||
| — | NCT06647056 | Dec 2024 → Jan 2025 | psychogenic movement disorders | Nîmes University Hospital | Completed | No outcome recorded |
| — | NCT06650800 | Nov 2024 → Mar 2025 | major depressive disorder, substance-related disorder | Nîmes University Hospital | Completed | No outcome recorded |
| — | NCT06529939 | Nov 2024 → Sep 2025 overdue | psychiatric disorder | Western University, Canada | Not yet recruiting | No outcome recorded |
| — | NCT06560658 | Oct 2024 → Oct 2025 | — | National University of Natural Medicine | Withdrawn | No outcome recorded Stop: Business |
| — | NCT06372197 | Aug 2024 → May 2025 | depressive disorder | Matthew Hicks | Completed | No outcome recorded |
| — | NCT06368492 | May 2024 → Dec 2025 overdue | fibromyalgia | Maastricht University | Recruiting | No outcome recorded |
| — | NCT05723276 | Feb 2024 → May 2026 overdue | conversion disorder | King's College London | Active not recruiting | No outcome recorded |
| — | NCT06235411 | Feb → Nov 2024 | alcohol dependence, depressive disorder | Nîmes University Hospital | Completed | No outcome recorded |
| — | NCT05651126 | Dec 2022 → Aug 2024 | autism spectrum disorder | King's College London | Completed | No outcome recorded |
| — | NCT05570708 | Oct 2022 → Jun 2029 expected | — | Felix Mueller | Enrolling by invitation | No outcome recorded |
| — | NCT03736980 | Oct 2013 → Dec 2018 | — | University of Zurich | Completed | No outcome recorded |
| — | NCT01943994 | Sep 2008 → May 2023 | nicotine dependence | Johns Hopkins University | Completed | Met primary |
| Comparator or background therapy30 trials | ||||||
| Phase 0 | NCT07449351 Comparator | Oct 2026 → Apr 2028 expected | — | Yale University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07818720 Comparator | Dec 2026 → Sep 2027 expected | premenstrual dysphoric disorder | MycoMedica Life Sciences PBC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07433452 Comparator | Sep 2026 → Sep 2028 expected | — | Gabriella Gobbi | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07693153 Comparator | Aug 2026 → Dec 2031 expected | — | Yale University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06989957 Comparator | Sep 2025 → Aug 2028 expected | post-traumatic stress disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT07180108 Background | Aug 2025 → Jun 2028 expected | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT07050368 Comparator | Jul 2025 → Jan 2026 | — | MycoMedica Life Sciences PBC | Completed | No outcome recorded |
| Phase 1 | NCT06815653 Background | Mar 2025 → Mar 2026 overdue | — | University College, London | Recruiting | No outcome recorded |
| Phase 1 | NCT06772753 Comparator | Feb 2025 → Jun 2027 expected | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT06643637 Comparator | Nov 2024 → Mar 2025 | — | MycoMedica Life Sciences PBC | Completed | No outcome recorded |
| Phase 1 | NCT06326606 Comparator | Mar → Jul 2024 | — | MycoMedica Life Sciences PBC | Completed | No outcome recorded |
| Phase 1 | NCT06081179 Comparator | Oct 2023 → Sep 2025 | — | University of Zurich | Completed | No outcome recorded |
| Phase 1 | NCT05523401 Comparator | Aug 2023 → Oct 2024 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT05317689 Comparator | May 2022 → Jan 2025 overdue | — | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04227756 Comparator | May 2020 → Sep 2022 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT02981173 Comparator | Dec 2016 → Jun 2022 | cluster headache syndrome | Yale University | Completed | No outcome recorded |
| Phase 1/2 | NCT06992999 Comparator | Sep 2026 → Dec 2028 expected | obsessive-compulsive disorder | Francisco A Moreno | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06885996 Comparator | Oct 2026 → Aug 2028 expected | post-traumatic stress disorder | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07306364 Comparator | Jun 2026 → Jun 2029 expected | chronic pain syndrome | Yale University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07169747 Comparator | Apr → Oct 2026 expected | anorexia nervosa | Region Skane | Recruiting | No outcome recorded |
| Phase 2 | NCT07072728 Comparator | Oct 2025 → Dec 2026 expected | adjustment disorder, breast cancer, cutaneous melanoma, endometrial cancer +4 | Psyence Australia Pty Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06592833 Comparator | Feb 2025 → Mar 2028 expected | major depressive disorder | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 2 | NCT06067737 Comparator | Feb 2024 → Jul 2028 expected | substance-related disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT06341426 Comparator | Feb 2024 → Jul 2026 overdue | major depressive disorder | University Health Network, Toronto | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05452772 Comparator | Nov 2023 → Dec 2026 expected | nicotine dependence | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT04410913 Comparator | Feb 2021 → Feb 2023 overdue | alcohol-related disorders | Keith Heinzerling | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04141501 Comparator | Jun 2020 → Mar 2023 | alcohol-related disorders | University of Zurich | Completed | No outcome recorded |
| Phase 2 | NCT03715127 Comparator | Mar 2019 → Oct 2021 | major depressive disorder | University of Zurich | Completed | No outcome recorded |
| Phase 2 | NCT00979693 Comparator | Jan 2012 → Apr 2013 | anxiety, melanoma | Multidisciplinary Association for Psychedelic Studies | Withdrawn | No outcome recorded |
| — | NCT05160220 Comparator | Jan → Jun 2021 | — | National Council of Scientific and Technical Research, Argentina | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 66
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | COMPASS Pathways | Results Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year compasspathways.com ↗ |
| 2026-07-16 | COMPASS Pathways | Results Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy compasspathways.com ↗
Documented speech production between participants and support providers during treatment administration sessions showed minimal interaction. |
| 2026-07-07 | COMPASS Pathways | Results Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile compasspathways.com ↗
New 6-month data supports COMP360’s potential to establish a new standard of care in TRD |
| 2026-05-29 | Optimi Health Corporation | Regulatory Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia optimi.net ↗
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage psychedelic pharmaceutical manufacturer, today acknowledged the final recommendations published by the Therapeutic Goods Administration ("TGA") following its targeted consultation on the Authorized Prescriber ("AP") scheme for psilocybin and MDMA. |
| 2026-05-08 | Filament Health Corp. | Results Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property filament.health ↗
Peer-reviewed results published yesterday (May 7, 2026) in JAMA Network Open demonstrate that a single dose of psilocybin meaningfully reduced cocaine use in adults with cocaine use disorder over six months, with no serious adverse events |
| 2026-04-24 | COMPASS Pathways | Regulatory Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher compasspathways.com ↗
today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). |
| 2026-02-17 | COMPASS Pathways | Results Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression compasspathways.com ↗
In COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS2 with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001)3 |
| 2026-01-07 | COMPASS Pathways | Regulatory Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD compasspathways.com ↗
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. |
| 2025-12-19 | Psyence Australia Pty Ltd | Regulatory Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial psyencebiomed.com ↗
today announced that the Bellberry Human Research Ethics Committee (HREC) has formally approved the use of PsyLabs’ psilocybin product (NPX5) in the Company’s ongoing Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in patients with cancer. |
| 2025-09-02 | COMPASS Pathways | Results Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder compasspathways.com ↗
today announced the publication of results from an open-label Phase 2 study evaluating the safety and tolerability of a single-dose of 25 mg of investigational COMP360 synthetic psilocybin treatment in 22 patients with post-traumatic stress disorder (PTSD). |
| 2025-07-31 | Filament Health Corp. | Regulatory Filament Health Announces First-Ever Compassionate Use Approval For Psilocybin In The European Union filament.health ↗ |
| 2025-07-07 | Filament Health Corp. | Regulatory Filament Health Announces FDA Authorization Of Phase 2 Clinical Trial Studying Psilocybin For Alcohol Use Disorder And Post-Traumatic Stress Disorder In Veterans and First Responders filament.health ↗ |
| 2025-06-23 | COMPASS Pathways | Results Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression compasspathways.com ↗
A single dose of COMP360 25 mg versus placebo demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.6 in change at the primary endpoint. |
| 2025-06-11 | Filament Health Corp. | Regulatory Filament Health Announces Authorization Of Phase 2 Clinical Trial Studying Botanical Psilocybin For Prolonged Grief Disorder filament.health ↗
Filament Health Corp. ( OTC:FLHLF ) (“ Filament ” or the “ Company ”), a clinical‐stage natural psychedelic drug development company, today announced that the Swedish Ethical Review Authority and the Swedish Medical Products Agency have authorized a double-blind phase 2 clinical trial studying its botanical psilocybin drug candidate, PEX010, at Linkoping University. |
| 2025-04-09 | Filament Health Corp. | Regulatory Filament Health Announces FDA Authorization Of Phase 2 Clinical Trial Studying PEX010, The Company's Botanical Psilocybin Drug Candidate, In Opioid Use Disorder filament.health ↗
today announces that the United States Food and Drug Administration (FDA) has authorized a phase 2 clinical trial study of its lead drug candidate, PEX010, at the University of Pennsylvania. |
| 2025-03-18 | COMPASS Pathways | Results Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression compasspathways.com ↗
The COMP004 study's findings suggest that over a 52-week period, a single administration of 25 mg COMP360 psilocybin demonstrated a longer maintenance of antidepressant effects compared to the 1 mg and 10 mg doses. |
| 2025-03-17 | Filament Health Corp. | Results Filament Health Announces Positive Data From Phase 2 Study Of PEX010 In Patients With Alcohol Use Disorder filament.health ↗
The results were published in the Journal of Psychopharmacology and found that a single 25mg dose of PEX010 was safe and effective in reducing alcohol consumption in AUD patients. |
| 2025-03-12 | Optimi Health Corporation | Regulatory Optimi Health Provides Corporate Update optimi.net ↗
Optimi has obtained the necessary BICON import permit for its natural psilocybin extract capsules, enabling their legal entry into Australia. |
| 2024-08-13 | TRYP Therapeutics | Results Tryptamine Therapeutics’ psilocybin trials deliver pain relief to all patients entropyneurodynamics.com ↗
The results, measured one month after the final dose, were remarkable: 100% of participants reported a clinically meaningful reduction in pain severity, sleep disturbances, and pain interference. |
| 2024-08-12 | TRYP Therapeutics | Results Tryptamine Therapeutics Deliver Encouraging Results Evaluating Psilocybin For Fibromyalgia entropyneurodynamics.com ↗
Importantly, the results highlighted that 100% of patients experienced reductions in fibromyalgia pain, sleep disturbance and pain interference during the trials. |
| 2024-08-12 | TRYP Therapeutics | Results Tryptamine Therapeutics achieves full patient response in TRP-8802 Phase 2a fibromyalgia trial entropyneurodynamics.com ↗
Tryptamine Therapeutics achieves full patient response in TRP-8802 Phase 2a fibromyalgia trial |
| 2024-08-12 | TRYP Therapeutics | Results ASX Health Stocks: Psilocybin drug shows promise for fibromyalgia pain relief entropyneurodynamics.com ↗
Every patient in the study reported improvements in pain, sleep, and overall quality of life one month after treatment. |
| 2024-06-03 | Filament Health Corp. | Regulatory Filament Health Announces Authorization Of Phase 2 Clinical Trial For PEX010 In The Treatment of Methamphetamine Use Disorder filament.health ↗
Filament Health Corp. ( OTCQB:FLHLF ) ( Cboe CA:FH ) ( FSE:7QS ) (“ Filament ” or the “ Company ”), a clinical‐stage natural psychedelic drug development company, today announced Health Canada and the United States Food and Drug Administration (“ FDA ”) authorization for a Phase 2 clinical trial of PEX010, Filament’s botanical psilocybin drug candidate, for the treatment of methamphetamine use disorder (“ MAUD ”). |
| 2024-05-08 | COMPASS Pathways | Results Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder compasspathways.com ↗
Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced top-line results from an open-label phase 2 study evaluating the safety and tolerability of investigational COMP360 psilocybin treatment in 22 patients with post-traumatic stress disorder (PTSD). |
| 2024-05-08 | COMPASS Pathways | Results Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights compasspathways.com ↗
We were pleased to see the positive results from the phase 2 PTSD study, a condition with significant unmet need and limited therapeutic options for the people who live with it. |
| 2024-03-21 | Psyence Australia Pty Ltd | Results Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin psyencebiomed.com ↗
The study presents evidence that nature (mushroom)-derived psilocybin delivers a “more potent and prolonged effect” on “neuroplasticity” than its synthetic analog. |
| 2024-03-07 | Psyence Australia Pty Ltd | Regulatory Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study psyencebiomed.com ↗
Psyence Biomedical Ltd (NASDAQ:PBM) (“Psyence Biomed” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Psyence Australia (Pty) Ltd (“Psyence Australia”), has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia. |
| 2024-01-31 | Filament Health Corp. | Regulatory Filament Health Announces FDA Opening Of Investigational New Drug Application For Substance Use Disorders filament.health ↗
The active IND allows initiation of US research with Filament’s botanical psilocybin drug candidate for the potential treatment of substance use disorders including OUD |
| 2023-12-19 | COMPASS Pathways | Results Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder compasspathways.com ↗
today announced that an initial data readout showed that investigational COMP360 psilocybin treatment was well-tolerated in a phase 2 clinical trial of people living with post-traumatic stress disorder (PTSD). |
| 2023-12-06 | COMPASS Pathways | Results Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry compasspathways.com ↗
All participants (n = 15) had lower MADRS scores with a mean change from baseline of -24.0 points at week 3, 12 participants met the response criteria and 11 met the remission criteria. |
| 2023-10-10 | Filament Health Corp. | Regulatory Filament Health Announces Health Canada Authorization For Phase 2 Clinical Trial Studying Botanical Psilocybin For Opioid Use Disorder filament.health ↗
Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, today announced Health Canada approval for a phase 2 clinical trial at the University of British Columbia (UBC). |
| 2023-09-07 | Optimi Health Corporation | Regulatory Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program optimi.net ↗
The amendment empowers Optimi to embark on the formal supply journey for Canada's Special Access Program (SAP), operating within the provisions of the Controlled Drugs and Substances Act and its Regulations. |
| 2023-09-06 | COMPASS Pathways | Results COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression compasspathways.com ↗
The peer-reviewed paper shows the AI model has the potential to predict outcomes of the investigational COMP360 psilocybin treatment in people with TRD up to 12 weeks after treatment using recordings taken during the integration session 24 hours post administration. |
| 2023-08-08 | Filament Health Corp. | Regulatory Filament Health Announces FDA Approval Of Two Clinical Trials Studying Its Botanical Psilocybin Drug Candidate PEX010 filament.health ↗
today announced approval from the United States Food and Drug Administration (FDA) for two clinical trials at leading American research institutions studying the effects of PEX010, Filament’s botanical psilocybin drug candidate, for mental health conditions including cancer-related anxiety and depression. |
| 2023-07-17 | COMPASS Pathways | Results COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology compasspathways.com ↗
Response (a greater than 50% reduction from baseline in MADRS total score1) and remission (MADRS total score of 10 or less) was seen in 42% of participants at week three. |
| 2023-07-13 | TRYP Therapeutics | Regulatory Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2a Clinical Trial In Patients With IBS At Massachusetts General Hospital entropyneurodynamics.com ↗
that the Company may proceed with its Phase 2a clinical trial at Massachusetts General Hospital (MGH) investigating the effects of psilocybin-assisted psychotherapy |
| 2023-05-30 | Filament Health Corp. | Results Filament Health Announces Interim Results From Phase I Clinical Trial At The University Of California San Francisco filament.health ↗
Fifteen doses of Filament’s drug candidates have been given, and all were reported to be well tolerated with no serious or unexpected adverse events. |
| 2023-05-26 | COMPASS Pathways | Results Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023 compasspathways.com ↗
More than half of the patients (16/28) treated with a single dose of 25mg COMP360 psilocybin with psychological support remained in remission from their depression at 18 months post administration. |
| 2023-05-24 | TRYP Therapeutics | Regulatory Tryp Therapeutics Submits Investigational New Drug (IND) Application To US FDA For Planned Phase 2a Clinical Trial In Patients With IBS At Massachusetts General Hospital entropyneurodynamics.com ↗
Tryp Therapeutics Submits Investigational New Drug (IND) Application To US FDA For Planned Phase 2a Clinical Trial In Patients With IBS At Massachusetts General Hospital |
| 2023-03-15 | Filament Health Corp. | Regulatory Filament Health Announces FDA Approval Of Phase II Clinical Trial Studying Psilocybin For Methamphetamine Use Disorder filament.health ↗
today announced approval from the United States Food and Drug Administration (FDA) for a clinical trial at the University ofCalifornia San Francisco’s Translational Psychedelic Research Program (TrPR). |
| 2023-02-07 | Optimi Health Corporation | Regulatory Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists optimi.net ↗ |
| 2023-01-18 | Filament Health Corp. | Regulatory Filament Health Announces Clinical Trial Approval In Partnership With Psychiatric Centre Copenhagen filament.health ↗
The trial, led by PhD student Mathias Ebbesen Jensen and Professor Anders Fink-Jensen, will study Filament’s natural psilocybin drug candidate for the treatment of alcohol use disorder (AUD) and was recently approved by the Danish Medicines Agency. |
| 2023-01-05 | TRYP Therapeutics | Results Tryp Therapeutics Announces Interim Results For Its Phase II Clinical Trial For The Treatment Of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy entropyneurodynamics.com ↗
TRP-8802 demonstrated significant and prolonged improvement in primary endpoints for all five patients |
| 2022-12-08 | COMPASS Pathways | Results COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP compasspathways.com ↗
The study, run by Dr Scott Aaronson at Sheppard Pratt Baltimore, found that 86% (12 out of 14) of the participants met response and remission criteria for the Montgomery-Åsberg Depression Rating Scale (MADRS) at 12 weeks after COMP360 psilocybin therapy. |
| 2022-11-10 | TRYP Therapeutics | Results Tryp Therapeutics Announces Poster Presentations On The Reduction Of Chronic Pain In A Rodent Model With Psilocybin And Intravenous Psilocybin Alters Brain Network Dynamics In Rats At The 2022 Society For Neuroscience Conference entropyneurodynamics.com ↗
The study results demonstrated that a single intravenous dose of psilocybin can attenuate mechanical allodynia and thermal hyperalgesia for up to 4 weeks post dose. |
| 2022-11-03 | COMPASS Pathways | Results COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine compasspathways.com ↗
After a single 25mg dose of COMP360 psilocybin, in combination with psychological support, 29.1% of participants with TRD were in remission by week 3 (p<0.002) |
| 2022-10-06 | Optimi Health Corporation | Regulatory Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health optimi.net ↗
It would give a physician, psychiatrist, or doctor the ability to prescribe and administer psilocybin, MDMA, or other psychedelics produced by Optimi to patients under the Mental Health Services Protection Act. |
| 2022-05-23 | COMPASS Pathways | Results COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting compasspathways.com ↗
The study showed that a single 25mg dose of COMP360 psilocybin, in combination with psychological support, was associated with a highly statistically significant reduction in depressive symptoms after three weeks (p<0.001), with a rapid and durable response for up to 12 weeks. |
| 2022-05-04 | Optimi Health Corporation | Regulatory Optimi Health Granted Amendment To Controlled Substances Dealer's Licence optimi.net ↗
Under the terms of the amendment, the Company is now permitted to possess a quota of up to 5000kg of dried psilocybin mushrooms - the equivalent of 10kg of psilocybin - and 100g of psilocin. |
| 2022-02-16 | Optimi Health Corporation | Regulatory Optimi Health Approved to Supply Psilocybin Under Health Canada's Special Access Program optimi.net ↗
Health Canada has added the Company's wholly-owned subsidiary Optimi Labs Inc. to a list of approved suppliers under the Special Access Program (SAP). |
| 2022-01-31 | Filament Health Corp. | Regulatory Filament Health and Cybin Therapeutics Announce Approval for Phase II Clinical Trial for Depression filament.health ↗
today announced Health Canada approval for a phase 2 clinical trial using PEX010, the Company’s botanical psilocybin drug candidate. |
| 2022-01-26 | Filament Health Corp. | Regulatory Filament Health Subsidiary Psilo Scientific Announces Inclusion in Health Canada List of Licensed Psilocybin Producers filament.health ↗ |
| 2022-01-04 | Filament Health Corp. | Regulatory Filament Health Announces Health Canada Approval for Phase II Trial Administering New Psilocybin Microdose Formulation filament.health ↗
today announced that Health Canada has approved a phase 2 clinical trial which will use the Company’s standardized natural psilocybin drug candidate PEX010 (1 milligram). |
| 2022-01-04 | COMPASS Pathways | Results COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology compasspathways.com ↗
The results also showed there were no short or long term detrimental effects on thinking patterns or processing of emotions. |
| 2021-12-20 | Usona Institute | Results Crystallographic Discoveries Bring New Clarity to Pharmaceutical Psilocybin Polymorph Characterization usonainstitute.org ↗
The study conclusively shows that three psilocybin polymorphs repeatedly occur from the well-known crystallization process and that they have appeared in numerous places throughout the history of synthesizing psilocybin since 1959. |
| 2021-12-13 | COMPASS Pathways | Results COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study compasspathways.com ↗
Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trial |
| 2021-12-01 | COMPASS Pathways | Results COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression compasspathways.com ↗
Additional analyses of primary and secondary endpoints validated topline findings and provided more insights into safety data. |
| 2021-11-09 | COMPASS Pathways | Results COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression compasspathways.com ↗
The 25mg group vs the 1mg group showed a -6.6 difference on the MADRS* depression scale at week 3 (p<0.001). |
| 2021-11-02 | Filament Health Corp. | Regulatory Filament Health Announces FDA Authorization of Clinical Trial with First-ever Direct Psilocin Administration and First-ever Psychedelic Botanical Drug Candidates filament.health ↗
Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7QS ) (“Filament” or the “Company”), an exclusively-natural psychedelic drug discovery company, announces FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances. |
| 2021-10-20 | COMPASS Pathways | Results Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups compasspathways.com ↗
Within one week of a single administration of COMP360 psilocybin therapy, 50% of participants achieved remission in depression symptoms, which was sustained for the eight week follow-up period. |
| 2021-06-03 | COMPASS Pathways | Results COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers compasspathways.com ↗
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists. |
| 2021-05-11 | Optimi Health Corporation | Regulatory Optimi Health and Numinus Wellness Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application optimi.net ↗
Optimi and Numinus, through Impact Clinical Trials Accelerator at the University of Calgary ("Impact"), have submitted a pre-clinical trial application to Health Canada for review and comment. |
| 2021-04-15 | COMPASS Pathways | Results New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder compasspathways.com ↗
Study concludes that psilocybin findings should be explored further in larger studies |
| 2019-12-12 | COMPASS Pathways | Results COMPASS Pathways and King’s College London announce results from psilocybin study in healthy volunteers compasspathways.com ↗
COMPASS Pathways, a mental health care company, has reported that its COMP360 (psilocybin) was well-tolerated when administered to healthy adult volunteers with support from specially trained therapists in a randomised placebo-controlled trial by King’s College London. |
| 2019-11-22 | Usona Institute | Regulatory FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder usonainstitute.org ↗
Usona Institute has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for psilocybin in the treatment of major depressive disorder (MDD). |
| 2018-10-23 | COMPASS Pathways | Regulatory COMPASS Pathways receives FDA Breakthrough Therapy designation for psilocybin therapy for treatment-resistant depression compasspathways.com ↗
COMPASS Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its psilocybin therapy for treatment-resistant depression. |
All press releases naming this drug 163 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 163 releases opens the full record — a long page | ||
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 281 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Psilocybin | “METHODS: Single, acute oral doses of DXM (400 mg/70 kg), psilocybin (10, 20, 30 mg/70 kg), and inactive placebo were administered under double-blind and psychologically...” PMID 38152462 ↗ Dec 2023272“2.0mg powdered psilocybin derived from Psilocybe cubensis mushrooms, in capsules, provided three times weekly for four weeks” NCT07449351 ↗ “Each participant will ingest psilocybin from dried mushrooms in a chocolate formulation.” NCT07275970 ↗ “one dose of 25 mg of oral psilocybin on the first dosing day” NCT06206265 ↗ “non-synthesized plant medicine psilocybin” NCT05042466 ↗ |
| Known as | 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate | “An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO)...” NCT04905121 ↗1“Psilocybin (\[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate), 25mg PO.” NCT06072898 ↗ |
| Known as | 4-hydroxy-N,N-dimethyltryptamine | “Psilocybin (4-hydroxy-N,N-dimethyltryptamine) occurs in nature in many species of mushrooms, including the genera Psilocybe, Conocybe, Gymnopilus, Panaeolus, and Strophparia.” NCT06442423 ↗ |
| Known as | 4-phosphoroyloxy-N,N-dimethyltryptamine | “Psilocybin (4-phosphoroyloxy-N,N-dimethyltryptamine) is a hallucinogenic tryptamine that was first isolated from Psilocybe mushrooms in 1957.” NCT02163707 ↗ |
| Known as | 4-phosphoryloxy- N,N-dimethyl-tryptamine | “Early clinical studies using the psychotropic compound psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) as an adjunct in psychotherapy reported a significant improvement of...” NCT03715127 ↗2“Psilocybin (4-phosphoryloxy- N,N-dimethyl-tryptamine) is a psychedelic (hallucinogenic) compound found in certain species of mushrooms” NCT00979693 ↗ “Participants may receive varying oral psychoactive doses of psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine)” NCT06772753 ↗ |
| Known as | BPL-PSILO | “An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO)...” NCT04905121 ↗ |
| Known as | COMP360 | “Participants (N=233) with treatment-resistant depression received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a synthesized, pharmaceutical-grade, proprietary...” PMID 41362124 ↗ Dec 20253“trial of escitalopram and investigational drug, COMP360, psilocybin, in the treatment of major depressive disorder” PMID 38247730 ↗ Jan 2024 “COMP360 (Brand name of psilocybin to be used)” NCT06247839 ↗ “Psilocybin (COMP360)” NCT06258031 ↗ |
| Known as | Magic Mushrooms | “Other Names: "Magic Mushrooms"” NCT05370911 ↗ |
| Known as | MLS101 | “The purpose of this trial is to investigate the safety and tolerability of intermittent low-dose MLS101 (psilocybin) 2mg, 4mg, and 8mg versus placebo in participants with PMDD.” NCT07818720 ↗1“MLS101 is being developed as a low dose psilocybin” NCT07050368 ↗ |
| Known as | NPX-5 | “Participants in Group 1 will receive a single dose of 25 mg NPX-5 psilocybin capsules under medical supervision on Day 14.” NCT07072728 ↗ |
| Known as | PEX010 | “A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom...” NCT04718792 ↗7“High Dose (25mg) PEX010 (Oral Psilocybin), 25mg; single dose (38 participants) administered 24hrs prior to first ACT session” NCT06885996 ↗ “Psilocybin PEX010 is an investigational drug provided in capsule form, containing a 25 mg dose of synthetic psilocybin.” NCT06815653 ↗ “Group 1: Psilocybin PEX010 (25 mg) + trazodone placebo (pharmaceutical master preparation prepared according to GPP)” NCT07210112 ↗ “The first session of psilocybin PEX010 administration will use a moderately high dose of psilocybin, i.e., 25 mg.” NCT07391332 ↗ “It will be in a capsule of 25mg psilocybin (PEX010).” NCT06378229 ↗ “PEX010 is the psilocybin produced by Filament” NCT06810310 ↗ “PSILOCYBIN (PEX010) 25 mg PO single dose” NCT06731335 ↗ |
| Known as | psi | “received zero, one, or two doses of psilocybin (10 mg; psi).” PMID 41459830 ↗ Dec 2025 |
| Known as | Psilocybine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06827054 ↗ |
| Known as | TRP-8802 | “Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy” NCT06206265 ↗ |
| Action | Activate | “classic psychedelics (5-HT2A receptor agonists or partial agonists) such as psilocybin might facilitate behavior change” PMID 36332827 ↗ Nov 2022 |
| Modality | Other / unclassified | “a serotonergic psychoactive agent” NCT00957359 ↗ |
| Route | Oral | “25 mg psilocybin administered orally once during each of the two day-long psychotherapy sessions” NCT00979693 ↗ |